- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00543829
German Preoperative Adriamycin Docetaxel Study
A Randomised, Controlled, Open Phase II b Study Comparing a Combination of Dose-Intensified Doxorubicin and Docetaxel With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast (T>=3cm N0-2 M0)
The primary objective of this trial is to determine the rate of pathologically complete remissions following a preoperative dose-intensified therapy with doxorubicin and docetaxel with or without tamoxifen in patients with operable carcinoma of the breast. Secondary aims are to assess the rate of clinical complete and partial responses, of breast-conserving operations, and the toxicity of chemotherapy with and without tamoxifen.
Women meeting the following criteria will be eligible for the study: operable breast cancer (T³3cm N0-2 M0), histologically confirmed diagnosis by core-cut needle or incisional biopsy, and measurable disease by mammography or sonography or breast MRI (best appropriate method has to chosen by investigator). After the patients have given written informed consent, they will be randomised to the study treatments. All patients are scheduled to receive 4 cycles of combination chemotherapy consisting of doxorubicin 50 mg/m² (15-min i.v. infusion) and docetaxel 75 mg/m² (1-h i.v. infusion). The patients allocated to group I additionally receive oral doses of tamoxifen 30 mg once daily, starting on the first day of chemotherapy, while chemotherapy alone is administered to patients of group II. Cycles should be repeated every 14 days, followed by surgery 8 weeks after initiation of the trial. Surgery consists of removal of the remaining tumour (breastconserving resection or mastectomy) and axillary dissection. Patients with no response or even progression of the primary tumour can be treated to the discretion of the investigator but should be followed up according to protocol. If a partial or complete tumour response has been achieved, radiotherapy is given to the remaining breast in patients undergoing breast conserving therapy, and tamoxifen treatment is continued for a further 5 years.
Response will be assessed between the 4th cycle and surgery, using the best appropriate method. Clinical evaluation should be performed after each cycle. It is planned to recruite 200 patients during a period of 1 year.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Unilateral primary carcinoma of the breast, confirmed histologically by core-cut needle or incisional biopsy. Fine needle aspiration is not sufficient.
- Bidimensionally measurable tumour, either by mammography or breast ultrasound or breast MRI
- Primary tumour >= 3 cm in largest diameter. In patients with multifocal or multicentric breast cancer the largest lesion should be measured.
- No evidence of distant metastases (as confirmed by chest x-ray, liver ultrasound and bone scintigraphy)
- Age >= 18 years and <= 70 years.
- Life expectancy at least 10 years, ignoring the diagnosis of cancer.
- Karnofsky index >=70%.
- Adequate haematologic, renal and hepatic function (WBC >4000, platelets >100000, bilirubin, serum creatinine and transaminases within the normal range).
- Anamnestic and electrocardiographic evidence of normal cardiac function, without or with medication. Normal cardiac function measured by echocardiography or MUGA-scan.
- Negative pregnancy test and appropriate non-hormonal contraception in fertile women.
- Written informed consent and presumed compliance of the patients.
Exclusion Criteria:
- Locally advanced (stage T4), bilateral, metastatic, or inflammatory breast cancer (tethering or dimpling of the skin as well as nipple inversion may not easily be interpreted as skin infiltration). If one of these conditions is suspected it has to be excluded before enrollment onto study.
- Previous treatment for breast cancer, including surgery, radiation, cytotoxic or endocrine treatments. Surgical diagnostic procedures are allowed.
- Previous malignancy other than breast cancer or non-invasive breast lesions if the disease-free interval is less than 10 years.
- Previous cytotoxic treatment for any condition.
- Preexisting neurotoxicity greater than grade II (WHO).
- Active infection or other significant illness that could influence tolerability of treatment.
- Current treatment with sex hormones (treatment has to be discontinued before the start of systemic therapy).
- Psychiatric illness or drug addiction that would preclude obtaining informed consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: 1
4 cycles of doxorubicin and docetaxel with tamoxifen
|
Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v.
infusion) and docetaxel (75 mg/m², 1 hour i.v.
infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
|
활성 비교기: 2
4 cycles of doxorubicin and docetaxel without tamoxifen
|
Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v.
infusion) and docetaxel (75 mg/m², 1 hour i.v.
infusion)
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
The primary endpoint is defined as no microscopic evidence of viable tumour in the resected breast specimen
기간: Post surgery
|
Post surgery
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Endpoints are (1) clinical partial or complete response and (2) clinical complete response
기간: Post surgery
|
Post surgery
|
Endpoint is breast conservation without the need for autologous or heterologous reconstruction
기간: Post surgery
|
Post surgery
|
Endpoints are the frequency of grade III and IV haematological and non-haematological toxicities during chemotherapy and delayed cardiotoxicity
기간: 2 years post surgery
|
2 years post surgery
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Manfred Kaufmann, MD, J. W. Goethe University, School of Medicine, Dep. of Gynecology and Obstetrics
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Gepardo
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
유방 신생물에 대한 임상 시험
doxorubicin, docetaxel, tamoxifen에 대한 임상 시험
-
Hebei Medical University Fourth Hospital완전한
-
NRG OncologyNational Cancer Institute (NCI)모병
-
Ayana Pharma Ltd.,Lambda Therapeutic Research Ltd.완전한
-
Tianjin Medical University Second HospitalCSPC Pharmaceutical Group Limited알려지지 않은
-
Duke UniversityNational Cancer Institute (NCI)종료됨
-
CelgeneGynecologic Oncology Group완전한나팔관암 | 상피성 난소암 | 원발성 복막암미국
-
AGO Study GroupEssex Pharma GmbH; MedServ. GmbH, Wiesbaden완전한자궁경부암 | 난소암, 2차 치료제로 치료 | 뮬러리안 혼합 종양 | 자궁 종양 | 비상피성 난소 종양독일